Voyageur Pharmaceuticals Ltd.
VM.V
TSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 78.61% | 179.73% | -12.07% | -8.93% | -53.38% |
| Depreciation & Amortization | -25.00% | -25.00% | -25.00% | -25.00% | -20.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.36% | 178.74% | -12.08% | -8.96% | -53.35% |
| Operating Income | -78.36% | -178.74% | 12.08% | 8.96% | 53.35% |
| Income Before Tax | -61.17% | -167.28% | 9.98% | 11.62% | 51.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.17% | -167.28% | 9.98% | 11.62% | 51.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.17% | -167.28% | 9.98% | 11.62% | 51.50% |
| EBIT | -78.36% | -178.74% | 12.08% | 8.96% | 53.35% |
| EBITDA | -78.61% | -179.73% | 12.07% | 8.93% | 52.74% |
| EPS Basic | -50.00% | -171.43% | 14.29% | 18.18% | 57.89% |
| Normalized Basic EPS | -87.50% | -140.00% | 13.64% | 14.29% | 66.67% |
| EPS Diluted | -50.00% | -171.43% | 14.29% | 18.18% | 57.89% |
| Normalized Diluted EPS | -87.50% | -140.00% | 13.64% | 14.29% | 66.67% |
| Average Basic Shares Outstanding | 5.05% | 5.08% | 4.66% | 7.23% | 18.85% |
| Average Diluted Shares Outstanding | 5.05% | 5.08% | 4.66% | 7.23% | 18.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |